Skip to Main Content

Paper Details

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Alzheimers Res Ther
4
2022

Datasets

Release 1.2